Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1755-1763

  Byers, Lauren Averett ^a   Christopher Holsinger, F ^a   Kies, Merrill S ^a   William, William N ^a   El Naggar, Adel K ^a   Lee, J Jack ^a   Hu, Jianhua ^a   Lopez, Adriana ^a   Tran, Hai T ^a   Yan, Shaoyu ^a   Du, Zhiqiang ^a   Ang, K Kian ^a   Glisson, Bonnie S ^a   Raso, Maria Gabriela ^a   Wistuba, Ignacio I ^a   Myers, Jeffrey N ^a   Hong, Waun Ki ^a   Papadimitrakopoulou, Vali ^a   Lippman, Scott M ^a   Heymach, John V ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; ANGIOGENIC FACTOR; CARBOPLATIN; CETUXIMAB; CONNECTIVE TISSUE GROWTH FACTOR; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CYTOKINE; EOTAXIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; INTERLEUKIN 13; INTERLEUKIN 16; MACROPHAGE INFLAMMATORY PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN; NERVE GROWTH FACTOR; PACLITAXEL; RECOMBINANT SCATTER FACTOR; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOCYTE; HEAD AND NECK CANCER; HEAD AND NECK CANCER SQUAMOUS CELL CANCER; HEAD AND NECK SQUAMOUS CELL CANCER; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SQUAMOUS CELL CARCINOMA; WART VIRUS;

ADULT; AGED; ANGIOGENESIS INDUCING AGENTS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CLUSTER ANALYSIS; CYTOKINES; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PAPILLOMAVIRIDAE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77953463905     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1047     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Thun MJ, American Cancer Society. Cancer facts & figures. Atlanta: American Cancer Society; 2008.
2. Vikram B, Strong EW, Shah JP, Spiro R. Second malignant neoplasms in patients successfully treated with multimodality treatment for advanced head and neck cancer. Head Neck Surg 1984;6:734-7. (Pubitemid 14185491)
3. Adam MF, Gabalski EC, Bloch DA, et al. Tissue oxygen distribution in head and neck cancer patients. Head Neck 1999;21:146-53.
4. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev 2002;2:38-47.
5. Kaanders JH, Wijffels KI, Marres HA, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-74.
6. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An internationalmulti-center study. Radiother Oncol 2005;77:18-24.
7. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001;61:5090-101.
8. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1α signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 2006;281:25903-14.
9. Denko NC, Fontana LA, Hudson KM, et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 2003;22:5907-14.
10. Winter SC, Buffa FM, Silva P, et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007;67:3441-9.
11. Gourin CG, Xia ZS, Han Y, et al. Serum protein profile analysis in patients with head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2006;132:390-7.
12. Linkov F, Lisovich A, Yurkovetsky Z, et al. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev 2007;16:102-7.
13. St John MA, Li Y, Zhou X, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 2004;130:929-35.
14. Wadsworth JT, Somers KD, Stack BC, Jr., et al. Identification of patients with head and neck cancer using serum protein profiles. Otolaryngol Head Neck Surg 2004;130:98-104.
15. Gourin CG, Moretz WH III, Weinberger PM, et al. Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2007;133:1125-30.
16. Allen C, Duffy S, Teknos T, et al. Nuclear factor-κB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 2007;13:3182-90.
17. Vidal L, Gillison ML. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am 2008;22:1125-42, vii.
18. Braakhuis BJ, Snijders PJ, Keune WJ, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004;96:998-1006.
19. Slebos RJ, Yi Y, Ely K, et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:701-9.
20. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010;28:8-14.
21. Dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL. Validation and comparison of Luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol 2005;66:175-91.
22. Giavedoni LD. Simultaneous detection of multiple cytokines and chemokines from nonhuman primates using Luminex technology. J Immunol Methods 2005;301:89-101.
23. Morgillo F, Bareschino MA, Bianco R, Tortora G, Ciardiello F. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 2007;75:788-99.
24. Shang ZJ, Li JR, Li ZB. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2002;31:495-8.
25. Riedel F, Zaiss I, Herzog D, Gotte K, Naim R, Hormann K. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res 2005;25:2761-5.
26. Hong SH, Ondrey FG, Avis IM, et al. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J 2000;14:1499-507.
27. Teknos TN, Cox C, Yoo S, et al. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 2002;24:1004-11.
28. Loukinova E, Dong G, Enamorado-Ayalya I, et al. Growth regulated oncogene-α expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 2000;19:3477-86.
29. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACHNC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55.
30. Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 2002;13:995-1006.
31. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004;22:1743-52.
32. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001;7:3399-403.
33. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:1192-202.